Login / Signup

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy.

Robert W MyersHong-Ping GuanJuliann EhrhartAleksandr PetrovSrinivasa PrahaladaEffie TozzoXiaodong YangMarc M KurtzMaria E TrujilloDinko Gonzalez TrotterDanqing FengShiyao XuGeorge EiermannMarie A HolahanDaniel J RubinsStacey ConarelloXiaoda NiuSandra C SouzaCorin MillerJinqi LiuKu LuWen FengYing LiRonald E PainterJames A MilliganHuaibing HeFranklin LiuAimie OgawaDouglas WisniewskiRory J RohmLiyang WangMichelle BunzelYing QianWei ZhuHongwu WangBindu M BennetLisa LaFranco ScheuchGuillermo E FernandezCai LiMichael KlimasGaochao ZhouMargaret van HeekTesfaye BiftuAnn WeberDavid E KelleyNancy ThornberryMark D ErionDaniel M KempIyassu K Sebhat
Published in: Science (New York, N.Y.) (2017)
5'-Adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of energy homeostasis in eukaryotes. Despite three decades of investigation, the biological roles of AMPK and its potential as a drug target remain incompletely understood, largely because of a lack of optimized pharmacological tools. We developed MK-8722, a potent, direct, allosteric activator of all 12 mammalian AMPK complexes. In rodents and rhesus monkeys, MK-8722-mediated AMPK activation in skeletal muscle induced robust, durable, insulin-independent glucose uptake and glycogen synthesis, with resultant improvements in glycemia and no evidence of hypoglycemia. These effects translated across species, including diabetic rhesus monkeys, but manifested with concomitant cardiac hypertrophy and increased cardiac glycogen without apparent functional sequelae.
Keyphrases